

**SHORT TITLE:** REVEAL

**RESEARCH PROTOCOL TITLE:** Randomized Evaluation of the Effects of Anacetrapib through Lipid Modification

**PRINCIPAL INVESTIGATOR:** David Lewis, MD

**RESEARCH SPONSOR:** The University of Oxford

**Clinical Trials.Gov Listing at:**

<http://clinicaltrials.gov/ct2/show/NCT01252953?term=reveal&rank=1>

**STUDY PURPOSE**

REVEAL is a study to see if raising levels of good cholesterol and further lowering levels of bad cholesterol can save more lives and reduce the chance of having a heart attack, stroke or other heart complications. REVEAL is doing this by testing a treatment called anacetrapib which is a drug that has been shown to raise levels of good cholesterol and lower levels of bad cholesterol in your blood.

**ELIGIBILITY CRITERIA FOR SUBJECTS**

Participants must be at least 50 years of age and have either:

1. a history of vascular disease (such as a heart attack, stroke, or peripheral arterial disease)
2. have diabetes with a history of chest pains requiring treatment or hospitalization

**SUBJECT PAYMENT**

Participants will be reimbursed \$50 for each completed study visit to compensate for time and travel expenses.

**RESEARCH LOCATION AND CONTACT PERSON**

Lynn Skatrud  
Meriter Wisconsin Heart  
2601 West Beltline Hwy.  
Suite 200  
Madison, WI 53713

**PHONE:** 608-417-2100